Artiva Biotherapeutics, Inc.
ARTV
$5.52
-$0.28-4.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -100.00% | -100.00% | -99.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -100.00% | -100.00% | -99.25% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -100.00% | -100.00% | -100.00% | -99.25% |
| SG&A Expenses | 17.81% | 31.51% | 48.08% | 37.84% | 23.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.98% | 35.47% | 33.53% | 24.46% | 5.26% |
| Operating Income | -33.48% | -41.25% | -156.22% | -172.84% | -119.37% |
| Income Before Tax | -28.29% | -29.38% | -131.51% | -176.98% | -128.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.29% | -29.23% | -131.00% | -176.21% | -127.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.29% | -29.23% | -131.00% | -176.21% | -127.62% |
| EBIT | -33.48% | -41.25% | -156.22% | -172.84% | -119.37% |
| EBITDA | -34.48% | -42.72% | -168.03% | -187.66% | -128.32% |
| EPS Basic | 91.60% | 94.10% | 91.79% | 24.12% | -13.43% |
| Normalized Basic EPS | 91.43% | 95.24% | 93.87% | 48.27% | 20.08% |
| EPS Diluted | 91.60% | 95.35% | 95.11% | 58.87% | 35.38% |
| Normalized Diluted EPS | 91.43% | 95.24% | 94.99% | 58.98% | 35.62% |
| Average Basic Shares Outstanding | 117.74% | 357.58% | 2,742.15% | 2,020.85% | 1,298.47% |
| Average Diluted Shares Outstanding | 117.74% | 357.58% | 879.02% | 629.03% | 379.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |